Muscular Dystrophy Canada Statement on Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA)
This past week, Muscular Dystrophy Canada (MDC) released a statement from Stacey Lintern, Chief Executive Officer of MDC on a Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA).
Statement from Dr. Hanns Lochmüller, Lead Investigator for NMD4C:
“We are thrilled to see our partners MDC collaborating with Novartis Pharmaceuticals Canada Inc to implement newborn screening as a standardized procedure across Canada. The strong national network of patient organizations, medical experts, researchers, and other stakeholders combined with investment from Novartis is a robust foundation on which to develop a national newborn screening plan.”
For many neuromuscular disorders, early diagnosis and prompt access to treatments are integral in achieving positive outcomes.
Unfortunately, this is not the reality for many patients who do not receive diagnoses until much later. For children born with Spinal Muscular Atrophy (SMA), newborn screening can identify children in need of treatment and care, which can drastically increase their chances of positive developmental outcomes.
Read next...
Applications Open for New NMD4C Collaborative Research Training Awards!
The NMD4C is excited to announce a new program for neuromuscular research trainees that will support collaboration opportunities between Canadian research labs.
NMD4C Members Receive Dr David Green Awards from Muscular Dystrophy Canada
We are excited to share that several NMD4C investigators and members have been honored with a Dr David Green Award from Muscular Dystrophy Canada!
Lower Extremity Muscle Strengthening Program in Myotonic Dystrophy Type 1 from Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
The Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) recently created a video aimed at health professionals that provides an in-depth explanation of the Myotonic dystrophy (DM1) training parameters used in their studies.
Fifth Annual Clinical Fellowship Competition from NMD4C and MDC Opens May 1st
The NMD4C and MDC clinical neuromuscular fellowship competition is accepting applications for the 2026 competition until June 12, 2025.
